NPG #14 Part 3 cover: Medication Selection, Procurement and Shortages, Introduction 101

Medication Selection, Procurement and Shortages: An Introduction (101)

In brief: NPG #14 requires hospitals to standardise and limit the number of drug concentrations available, to communicate medication shortages and outages to staff, and to follow written substitution protocols during shortages (Joint Commission, 2025). Corpus studies link shortages and unplanned substitutions to medication errors (Park et al., 2025; Said et al., 2018), and standard concentrations to fewer infusion errors, especially in children (Hilmas et al., 2010).

Prof. Dr. Mehmet Nurullah Kurutkan, Düzce University, Faculty of Business, Department of Health Management

Abstract. Part 3 turns from the bedside to the supply chain. Using 122 hospital records from a 4,936-record Web of Science corpus, it explains how decisions about which drugs and which strengths a hospital stocks shape error risk. The chapter covers concentration standardisation, drug shortages, therapeutic substitution and formulary control, and shows that the strongest evidence comes from paediatric standard-concentration infusions, while shortage research is still largely survey based with a small number of causal studies.

Learning objectives

After completing this chapter, the reader will be able to:

  1. Explain the three selection and procurement requirements of NPG #14.
  2. Define standard concentration infusions, drug shortage, therapeutic substitution and formulary management.
  3. Describe how shortages create medication errors through unfamiliar products, doses and substitutions.
  4. Summarise the evidence on standard concentrations in paediatric and neonatal care.
  5. Evaluate the quality of evidence linking shortages to patient harm.
  6. Draft a shortage communication and substitution protocol for a hospital.

Key concepts: standard concentration infusion, drug shortage, therapeutic substitution (interchange), generic substitution, formulary, non-formulary medication, drug change

Contents

  • 1. Introduction
  • 2. History and development
  • 3. Definitions and conceptual schema
  • 4. Distinguishing neighbouring concepts
  • 5. Types and classifications
  • 6. Theoretical frameworks and models
  • 7. Themes and bibliometric profile
  • 8. The situation in Türkiye
  • 9. Debates and contradictions in the literature
  • 10. Measurement problems
  • 11. Research gaps and agenda
  • 12. Relevance today and practical implications
  • Summary box, discussion questions, further reading, glossary and references

Method box: how this chapter was produced

ComponentApplication
Source documentJoint Commission (2025), National Performance Goal #14 “Effectively Managing Medications” (formerly part of the National Patient Safety Goals). (Joint Commission, 2025)
Database and indexesWeb of Science Core Collection (SCI-EXPANDED, SSCI, ESCI)
Search strategy (series)Seven component blocks derived from the NPG #14 requirements, a core medication safety block and a hospital context block; combined set #24 = ((#1 AND component blocks 1-4) OR medication reconciliation OR anticoagulant block) AND hospital block, OR the title-based stewardship block; filtered to articles and reviews, English, 2000-2026.
Component query (this chapter)TS=("drug shortage*" OR "medication shortage*" OR "drug supply shortage*" OR "medication substitution" OR "therapeutic substitution" OR "drug substitution" OR "standardized concentration*" OR "standardised concentration*" OR "concentration standardi*" OR "standard concentration*" OR "hospital formular*" OR "formulary management" OR "medication procurement" OR "drug procurement"), combined with the core medication safety block
Core blockTS=("medication safety" OR "medication error*" OR "medication mistake*" OR "drug error*" OR "prescribing error*" OR "prescription error*" OR "dispensing error*" OR "administration error*" OR "transcription error*" OR "adverse drug event*" OR "preventable adverse drug*" OR "medication-related harm" OR "medication incident*" OR "medication management" OR "medication use process" OR "safe medication" OR "high-alert medication*" OR "wrong drug" OR "wrong dose" OR "wrong route")
Search date and span16 November 2026; publication years 2000-2026 (2027 early-access records retained)
Inclusion and exclusionIncluded: hospital-context records matching this component. Excluded: retracted publications and records whose only labeling match was “open-label”.
Screening countsSeries corpus 4,936; tagged for this component 122; excluded 0; eligible 122; core evidence set (component term in title or author keywords) 32; “patient safety” framed 33.
Evidence extractionDefinitions, milestones, models, measures, debates and gaps were extracted from the abstracts of the most cited and most recent records in the core set.
LimitationsSingle database; English only; component tagging is rule based and reproduces the WoS query on title, abstract and keywords (agreement within 5 records per component); evidence read at abstract level; full texts were not read.
Medication Selection, Procurement and Shortages: from the series corpus to the evidence setIdentification: 4,936 recordsWoS Core Collection, set #24, 16 Nov 2026Component tagging: 122 recordsComponent query re-applied to TI, AB, AK, KPEligible component subcorpus: 12233 also use "patient safety" framingCore evidence set: 32 recordsComponent term in title or author keywordsExcluded: 0 recordsRetracted publication or “open-label”match only (label noise)Background layer: 90Match in abstract or Keywords Plus only
Figure 1. Flow of records for Part 3. Counts match the screening sheet of the supplementary workbook. Source: produced by the author from the corpus.

1. Introduction

When a drug runs out, clinicians receive a different product, a different strength or a different molecule, often at short notice. Each change is a new opportunity for error. In a survey of German reference pharmacies, about one in five community and hospital pharmacies reported medication errors related to shortages (Said et al., 2018). A causal study of heparin supply disruptions after Hurricane Maria concluded that common mitigation measures such as substitution may themselves be unsafe (Park et al., 2025).

NPG #14 therefore places selection and procurement inside medication safety: fewer concentrations, clear shortage communication and written substitution rules (Joint Commission, 2025). This chapter explains the logic behind each element.

2. History and development

Formulary control was already linked to safety in the 2000s: an audit of non-formulary orders found that most did not meet institutional criteria and frequently contained prescribing errors (Pummer et al., 2009). A 2005 study documented adverse events after a shortage-driven therapeutic interchange (Sheth et al., 2005). In 2008 Canadian accreditation endorsed standard concentrations of high-alert infusions in paediatrics (Irwin et al., 2008), and a comprehensive paediatric system with standard concentrations followed in 2010 (Hilmas et al., 2010).

The 2010s brought shortage research: national surveys in Canadian anaesthesia (Hall et al., 2013) and emergency medicine reviews (Mazer-Amirshahi et al., 2014), European statements on selection and procurement (Horák et al., 2018), and evidence that standard concentrations are often implemented locally without true harmonisation (Oskarsdottir et al., 2018). Since 2020 the field has used dashboards (Lux et al., 2022), systematic reviews (Wende et al., 2025) and natural experiments (Park et al., 2025). NPG #14 now lists all three procurement elements (Joint Commission, 2025).

Milestones: Medication Selection, Procurement and Shortages2005Adverse events aftershortage interchange2008Accreditation endorsesstandard paediatricconcentrations2010Generic and therapeuticsubstitution debate2013Shortages in Canadiananaesthesia2017Standard morphineinfusions in PICU2018Shortages linked toerrors in German survey2022State drug shortagedashboard2025Heparin shortage linkedcausally to errors; NPG#14
Figure 2. Milestones drawn from the Joint Commission fact sheet and dated corpus records cited in this section. Source: produced by the author from the corpus.

3. Definitions and conceptual schema

The subcorpus defines its concepts from three directions: clinical (concentrations), economic (substitution) and supply chain (shortages).

SourceYearDisciplineDefinition (paraphrased)Emphasised dimension
Perkins et al. (2017)2017Paediatric critical careStandard concentrations of intravenous infusions are fixed concentrations chosen to cover weight ranges within fluid limits, advocated to increase infusion safety.Fewer calculation and preparation steps
Duerden & Hughes (2010)2010Clinical pharmacologyGeneric substitution switches brand to generic; therapeutic substitution switches to a different drug of the same class.Cost versus individual risk
Mazer-Amirshahi et al. (2014)2014Emergency medicinePrescription drug shortages are increasingly common, longer and more severe, with multifactorial causes such as manufacturer consolidation, quality problems and weak financial incentives.Supply disruption and its causes
Poulsen et al. (2019)2019Patient safetyDrug change is a common challenge in hospitals that affects staff work and has potentially serious patient safety consequences.Workload and error from change
Joint Commission (2025)2025AccreditationSelection and procurement includes limiting concentrations, communicating shortages and following written substitution protocols.Organisational control
Table 1. Definition comparison.

The common core is that every product a hospital stocks, and every change to that set, carries error risk. Definitions diverge on whether the problem is variety (too many concentrations), scarcity (shortage) or change (substitution), and on whether the remedy lies with clinicians, pharmacy or the supply system.

Conceptual schema: Medication Selection, Procurement and ShortagesVariety: number ofconcentrationsScarcity: shortages andoutagesChange: substitutionprotocolsCommunication to staffFormulary governanceSupply chain resilienceSafe selection and procurementcontrolling which products,strengths and changes reachthe ward
Figure 3. The shared core of the definitions (centre) and the dimensions on which they diverge (outer boxes). Source: produced by the author from the corpus.

4. Distinguishing neighbouring concepts

Selection and procurement overlaps with formulary management, generic substitution and supply chain management. Formulary management decides which drugs are available; generic substitution is mainly driven by cost (Duerden & Hughes, 2010); supply chain management concerns availability. NPG #14 adds a safety lens: the question is not only whether a drug is available and affordable but whether the way it is made available introduces error.

A useful distinction is between planned standardisation (choosing fewer concentrations in advance) and reactive change (substituting during shortages). The first reduces error opportunities; the second increases them unless guided by protocol (Park et al., 2025; Sheth et al., 2005).

Neighbouring concepts comparedPrimary aim issafetyPlanned inadvanceTriggered bysupply failureChanges productat the bedsidePharmacy ledConcentration standardisationShortage substitution protocolGeneric substitutionFormulary managementSupply chain managementcentral featurepartial or context-dependentnot a defining feature
Figure 4. Distinguishing criteria between the focal concept (first row) and neighbouring concepts. Source: produced by the author from the corpus.

5. Types and classifications

The subcorpus covers three families of interventions.

FamilyTypical interventionCorpus evidence
Concentration standardisationLimited list of infusion concentrations, often with smart pumps or prefilled syringesErrors eliminated or reduced in paediatric systems (Hilmas et al., 2010; Rashed et al., 2019); safe in PICU (Arenas-López et al., 2017)
Shortage managementEarly warning, communication, dashboards, alternative agentsSurveys and reviews (Clark et al., 2020; Said et al., 2018); state dashboard (Lux et al., 2022)
Substitution and formulary controlWritten interchange protocols, non-formulary criteriaAdverse events after interchange (Sheth et al., 2005); prescribing errors in non-formulary orders (Pummer et al., 2009)
Table 2. Intervention families in selection and procurement.

6. Theoretical frameworks and models

Two frameworks dominate. The error-opportunity model holds that each extra concentration, calculation or product change adds a chance of error; standardisation reduces the number of steps (Perkins et al., 2017). The resilience model, prominent in recent shortage reviews, treats shortages as a system property requiring early warning, data sharing and policy (Yi et al., 2026).

Organisational studies add a work-system view: drug changes are experienced by staff as a burden at individual and organisational levels, and pharmacy personnel play a key role in keeping them safe (Poulsen et al., 2019).

7. Themes and bibliometric profile

The eligible subcorpus holds 122 records (15 of them reviews) with 2,055 citations in the WoS Core Collection. 25 records appeared in 2000-2010 and 80 in 2016-2026, so most of the evidence is recent (Figure 5). The leading journals are American Journal of Health-system Pharmacy (19), European Journal of Hospital Pharmacy (7), Hospital Pharmacy (7), Annals of Pharmacotherapy (3). By author address the most active countries are United States (54), England (13), Germany (9), Saudi Arabia (7), France (6). The most frequent author keywords are: medication safety, medication errors, patient safety, hospitals, errors, medication, pharmaceutical services, pharmacy, pharmacists, hospital, prescribing, medication error. 33 records (27%) explicitly frame their topic with the term “patient safety”.

Three themes stand out: (1) paediatric and neonatal infusions, where most standardisation evidence comes from (De Basagoiti et al., 2022; Irwin et al., 2008; Oskarsdottir et al., 2018); (2) shortages in acute specialties such as anaesthesia, emergency and neurocritical care (Clark et al., 2020; Hall et al., 2013; Mazer-Amirshahi et al., 2014); (3) European and national policy on procurement (Horák et al., 2018).

Publications per year: Medication Selection, Procurement and Shortages04811152000: 020002001: 12002: 12003: 02004: 22005: 220052006: 12007: 12008: 52009: 42010: 820102011: 42012: 62013: 32014: 12015: 320152016: 12017: 82018: 62019: 152020: 720202021: 82022: 112023: 32024: 42025: 92026: 82026Records per publication year (n = 122); 2026 is a partial year (lighter bar). 2027 early-access records are omitted.
Figure 5. Annual output of the eligible subcorpus, 2000-2026. Source: produced by the author from the corpus.

8. The situation in Türkiye

No record in this subcorpus has a Turkish address. Selection, shortage and substitution practices in Turkish hospitals are therefore not covered by the corpus; this is a notable gap given that shortages are global (Yi et al., 2026).

9. Debates and contradictions in the literature

Axis 1: is substitution a price worth paying? From a system perspective substitution may be acceptable because of opportunity costs, even if it raises error risk for individuals (Duerden & Hughes, 2010). Patient safety studies show harm after interchange (Sheth et al., 2005) and argue that substitution during shortages may be unsafe (Park et al., 2025).

Axis 2: how strong is the evidence for standard concentrations? Single-centre studies report eliminated or reduced errors (Hilmas et al., 2010; Rashed et al., 2019), but a 2025 systematic review judged the evidence limited and heterogeneous (Wende et al., 2025).

Axis 3: local or national standardisation? Local implementation produced wide variation and “no true standardisation” in the United Kingdom (Oskarsdottir et al., 2018) and low, inconsistent implementation in Spanish neonatal units (De Basagoiti et al., 2022), which supports national harmonisation.

10. Measurement problems

Shortage-related harm is mostly measured by self-reported surveys of pharmacists or physicians (Alyami et al., 2023; Hall et al., 2013; Said et al., 2018), which capture perceptions rather than event rates. Causal designs remain rare; the heparin study is an exception (Park et al., 2025).

Standard-concentration studies measure errors through incident reports or pump logs, with different denominators across units. Some use indirect safety outcomes such as fluid balance (Cree et al., 2018). There is no agreed indicator for “number of concentrations available” or for the timeliness of shortage communication.

11. Research gaps and agenda

The following questions are framed so that they can be answered by empirical studies; each notes the evidence gap it derives from.

  1. What is the incidence of harmful medication errors attributable to shortages in hospitals? (Most evidence is survey based.)
  2. Do national standard concentration lists reduce paediatric infusion errors more than local lists? (Local variation documented; no comparative trial.)
  3. Which shortage communication channels reach front-line staff in time? (No evaluation of communication itself.)
  4. Do written substitution protocols reduce errors compared with ad hoc substitution? (Harm after interchange reported; protocol effect untested.)
  5. How do shortages affect medication safety in middle-income countries such as Türkiye? (No Turkish record.)
  6. Can shortage dashboards predict and prevent safety events? (Dashboards described, not evaluated for safety.)

12. Relevance today and practical implications

A practical NPG #14 package has four parts: (1) a pharmacy and therapeutics committee list of approved concentrations for high-alert infusions, aligned with national lists where they exist (Oskarsdottir et al., 2018); (2) a shortage alert procedure that names who informs prescribers, nurses and the electronic order system (Mazer-Amirshahi et al., 2014); (3) written substitution protocols with dose conversion and monitoring for adverse events (Sheth et al., 2005); (4) a review of non-formulary orders (Pummer et al., 2009).

Summary box

  • Every product and every change in the drug supply carries error risk.
  • NPG #14 requires fewer concentrations, shortage communication and written substitution protocols.
  • Standard concentrations reduce infusion errors in single-centre paediatric studies, but systematic evidence is limited.
  • Shortages are linked to errors mainly through surveys, with one causal natural experiment.
  • Local standardisation without national harmonisation leaves wide variation.
  • The corpus contains no Turkish evidence on this requirement.

Discussion questions

  1. Why does reducing the number of available concentrations reduce errors?
  2. When might therapeutic substitution be justified despite added risk?
  3. What makes survey evidence on shortages weaker than event data?
  4. How could a national standard concentration list help small hospitals?
  5. Application: write a five-step shortage communication procedure for your hospital.
  6. Application: design a substitution protocol for a common shortage (for example, an antiemetic).

Further reading

  • Hilmas et al. (2010): a complete standard-concentration system and its safety effect.
  • Park et al. (2025): rare causal evidence linking a shortage to medication errors.
  • Duerden & Hughes (2010): the cost and safety trade-off in substitution.
  • Oskarsdottir et al. (2018): why local standardisation is not enough.
  • Yi et al. (2026): a global scoping review of shortage prevention.

Glossary

TermTurkishShort definition
Standard concentration infusionStandart konsantrasyonlu infüzyonInfusion prepared at one of a few fixed concentrations.
Drug shortageİlaç yokluğu / tedarik sıkıntısıSupply of a drug does not meet demand.
Therapeutic substitutionTerapötik ikameReplacing a drug with a different agent of similar effect.
Generic substitutionJenerik ikameReplacing a brand with a generic of the same molecule.
FormularyHastane ilaç listesi (formüler)List of drugs approved for use in the hospital.
Drug changeİlaç değişikliğiReplacement of a stocked product by another.
High-alert medicationYüksek riskli ilaçDrug with heightened risk of harm when used in error.

References

Alyami, H. S., Naser, A. Y., Alyami, M. H., Al Garsan, M., Al-Nahdi, A. Y., Alalhareth, I. S., & Alyami, S. M. (2023). Drug shortages in Najran region, Saudi Arabia: A cross-sectional survey. Clinical Epidemiology and Global Health, 21, 101305. https://doi.org/10.1016/j.cegh.2023.101305

Arenas-López, S., Stanley, I. M., Tunstell, P., Aguado-Lorenzo, V., Philip, J., Perkins, J., Durward, A., Calleja-Hernández, M. A., & Tibby, S. M. (2017). Safe implementation of standard concentration infusions in paediatric intensive care. Journal of Pharmacy and Pharmacology, 69(5), 529-536. https://doi.org/10.1111/jphp.12580

Clark, S. L., Levasseur-Franklin, K., Pajoumand, M., Barra, M., Armahizer, M., Patel, D., Chester, K. W., & Tully, A. P. (2020). Collaborative Management Strategies for Drug Shortages in Neurocritical Care. Neurocritical Care, 32(1), 226-237. https://doi.org/10.1007/s12028-019-00730-7

Cree, M. L., Stocker, C. F., Tu, Q. M., & Scaini, L. F. (2018). Adherence to standard medication infusion concentrations and its impact on paediatric intensive care patient outcomes. Australian Critical Care, 31(4), 213-217. https://doi.org/10.1016/j.aucc.2017.07.003

De Basagoiti, A., Antón, X., Calleja, A., De Miguel, M., Guerra, E., Loureiro, B., & Campino, A. (2022). Analysis of standard concentrations of continuous infusions in nine Spanish neonatal intensive care units. European Journal of Hospital Pharmacy, 29(1), 50-54. https://doi.org/10.1136/ejhpharm-2019-002194

Duerden, M. G., & Hughes, D. A. (2010). Generic and therapeutic substitutions in the UK: are they a good thing?. British Journal of Clinical Pharmacology, 70(3), 335-341. https://doi.org/10.1111/j.1365-2125.2010.03718.x

Hall, R., Bryson, G. L., Flowerdew, G., Neilipovitz, D., Grabowski-Comeau, A., & Turgeon, A. F. (2013). Drug shortages in Canadian anesthesia: a national survey. Canadian Journal of Anesthesia Journal Canadien D Anesthesie, 60(6), 539-551. https://doi.org/10.1007/s12630-013-9920-z

Hilmas, E., Sowan, A., Gaffoor, M., & Vaidya, V. (2010). Implementation and evaluation of a comprehensive system to deliver pediatric continuous infusion medications with standardized concentrations. American Journal of Health-system Pharmacy, 67(1), 58-69. https://doi.org/10.2146/ajhp080598

Horák, P., Underhill, J., Batista, A., Amann, S., & Gibbons, N. (2018). EAHP European Statements Survey 2017, focusing on sections 2 (Selection, Procurement and Distribution), 5 (Patient Safety and Quality Assurance) and 6 (Education and Research). European Journal of Hospital Pharmacy, 25(5), 237-244. https://doi.org/10.1136/ejhpharm-2018-001659

Irwin, D., Vaillancourt, R., Dalgleish, D., Thomas, M., Grenier, S., Wong, E., Wright, M., Sears, M., Doherty, D., & Gaboury, I. (2008). Standard concentrations of high-alert drug infusions across paediatric acute care. Paediatrics & Child Health, 13(5), 371-376. https://doi.org/10.1093/pch/13.5.371

Joint Commission. (2025). Effectively managing medications (National Performance Goal #14) [Fact sheet]. https://digitalassets.jointcommission.org/api/public/content/d0c3745c2d7e494ca5199bd3af2a13bc

Lux, K., Jorns, M., & Vogler, C. (2022). Creation of a State Drug Shortage Dashboard in the COVID-19 Pandemic. Hospital Pharmacy, 57(4), 474-481. https://doi.org/10.1177/00185787211046861

Mazer-Amirshahi, M., Pourmand, A., Singer, S., Pines, J. M., & Van Den Anker, J. (2014). Critical Drug Shortages: Implications for Emergency Medicine. Academic Emergency Medicine, 21(6), 704-711. https://doi.org/10.1111/acem.12389

Oskarsdottir, T., Harris, D., Sutherland, A., Wignell, A., & Christiansen, N. (2018). A national scoping survey of standard infusions in paediatric and neonatal intensive care units in the United Kingdom. Journal of Pharmacy and Pharmacology, 70(10), 1324-1331. https://doi.org/10.1111/jphp.12992

Park, M., Carson, A. L., & Conti, R. M. (2025). Linking Medication Errors to Drug Shortages: Evidence from Heparin Supply Chain Disruptions Caused by Hurricane Maria. M&som-manufacturing & Service Operations Management, 27(4). https://doi.org/10.1287/msom.2023.0297

Perkins, J., Aguado-Lorenzo, V., & Arenas-Lopez, S. (2017). Standard concentration infusions in paediatric intensive care: the clinical approach. Journal of Pharmacy and Pharmacology, 69(5), 537-543. https://doi.org/10.1111/jphp.12604

Poulsen, J. H., Rishoj, R. M., Fischer, H., Kart, T., Norgaard, L. S., Sevel, C., Dieckmann, P., & Clemmensen, M. H. (2019). Drug change: ‘a hassle like no other’. An in-depth investigation using the Danish patient safety database and focus group interviews with Danish hospital personnel. Therapeutic Advances in Drug Safety, 10, 2042098619859995. https://doi.org/10.1177/2042098619859995

Pummer, T. L., Shalaby, K. M., & Erush, S. C. (2009). Ordering Off the Menu: Assessing Compliance with a Nonformulary Medication Policy. Annals of Pharmacotherapy, 43(7-8), 1251-1257. https://doi.org/10.1345/aph.1M098

Rashed, A. N., Whittlesea, C., Davies, C., Forbes, B., & Tomlin, S. (2019). Standardised concentrations of morphine infusions for nurse/patient-controlled analgesia use in children. BMC Anesthesiology, 19, 26. https://doi.org/10.1186/s12871-019-0697-7

Said, A., Goebel, R., Ganso, M., Zagermann-Muncke, P., & Schulz, M. (2018). Drug shortages may compromise patient safety: Results of a survey of the reference pharmacies of the Drug Commission of German Pharmacists. Health Policy, 122(12), 1302-1309. https://doi.org/10.1016/j.healthpol.2018.09.005

Sheth, H. S., Verrico, M. M., Skledar, S. J., & Towers, A. L. (2005). Promethazine adverse events after implementation of a medication shortage interchange. Annals of Pharmacotherapy, 39(2), 255-261. https://doi.org/10.1345/aph.1E361

Wende, L., Schoberer, M., Kaune, A., Kreutzer, K. B., Orlikowsky, T., Christiansen, N., Nydert, P., Schubert, S., & Eisert, A. (2025). The Effect of Standard Concentration Infusions on Medication Errors in Neonatal and Pediatric Healthcare Settings: A Systematic Review. Journal of Clinical Medicine, 14(22), 7965. https://doi.org/10.3390/jcm14227965

Yi, Q. S., Yang, N., Zeng, L. A., Huang, L., Zou, K., Chen, J. J., Luo, J. F., Zhang, M., Diao, S., Yu, Q., Zhu, Y. Z., Han, L., & Zhang, L. L. (2026). How to alleviate the shortage: a scoping review of prevention and management of global drug shortages. BMC Public Health, 26(1), 1149. https://doi.org/10.1186/s12889-026-26834-2

Source verification note

Author names, year, journal and DOI details of the 22 corpus-based citations were generated by code directly from the Web of Science records and checked one to one against the in-text citations; claims were checked at the level of record abstracts, and full texts were not read. The Joint Commission fact sheet was read in full on 16 November 2026. No source outside the corpus and the fact sheet is cited.

AI use statement

Anthropic’s Claude model was used to design and run the Web of Science search, tag and pre-screen records, extract evidence from abstracts, draft the English text and produce the figures. Final decisions, the scientific accuracy of the text and final responsibility rest with the author.

Data and supplementary material

The full list of the 32 core records and the 122 eligible records for this part (author, year, title, journal, DOI, component flags, “patient safety” layer flag and pre-screening suggestion), the screening log of the 4,936-record series corpus and the citation verification report are provided in the series companion workbook (NPG14_Series_Supplementary.xlsx), available from the author on request. The record list is deliberately kept out of the chapter text.

Cite this page (APA 7)

Kurutkan, M. N. (2026, November 16). Medication Selection, Procurement and Shortages: An Introduction (101). The Health Topics. https://healthtopic.org/topics/medication-selection-procurement-and-shortages-an-introduction-101/

Subscribe to the Health Topics Newsletter!

Google reCaptcha: Invalid site key.